Transient ischemic attack (TIA), commonly known as a mini-stroke, is a transient episode of neurological dysfunction caused by focal brain or retinal ischemia without acute infarction. TIAs have the same underlying pathogenic mechanisms as strokes, including thrombosis, embolism, or systemic hypoperfusion. Diagnosing TIAs is critical as it can help predict future risk of major stroke and guide acute preventive treatment. TIAs are typically diagnosed by comprehensive patient history, neurological examination, and diagnostic testing including imaging of the brain and vessels supplying the brain.

The Global Transient Ischemic Attack Market is estimated to be valued at USD 1.34 Bn in 2024 and is expected to reach USD 2.03 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.

Key Takeaways

Key players operating in the transient ischemic attack diagnostics are Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Cordis Corporation, Koninklijke Philips N.V., Siemens Healthineers AG.

 Early detection and treatment of Transient Ischemic Attack Market Demand significantly reduce the risk of long-term disability from stroke. With growing awareness about early diagnosis of TIAs, the demand for diagnostic tests and monitoring devices is increasing globally. Major players are focusing on geographical expansion and launch of innovative diagnostic products to strengthen their presence in the high-growth emerging TIA diagnostics market.

Get More Insights On- Thermostat Market

Get this Report in Japanese Language: 過性脳虚血発作市場

Get this Report in Korean Language: 일과성허혈성발작시장